Hosted on MSN37m
Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...
Bernstein cuts Regeneron stock price target to $1,000, keeps Outperform
Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.
JD Supra18h
Personal Jurisdiction Over Foreign Companies that File an ANDA or aBLA in the U.S.
On January 29, 2025, the Federal Circuit issued paired decisions addressing Samsung Bioepis’s (“SB”) and Formycon AG’s ...
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...
CIO21h
Join Lee Rennick at the CIO100 with Bob McCowan, SVP & CIO, Regeneron, on CIO Leadership Live
Join Lee Rennick from the CIO100 with Bob McCowan, SVP & CIO, Regeneron as he discusses the award-winning Centralized Data ...
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...